Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C. Vidal C, et al. Among authors: clotet b. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60. doi: 10.1097/00042560-199809010-00009. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732070 Clinical Trial.
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J. Gatell JM, et al. Among authors: clotet b. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):249-58. doi: 10.1097/00042560-199607000-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8673528 Clinical Trial.
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Ruiz L, Nijhuis M, Boucher C, Puig T, Bonjoch A, Martínez-Picado J, Marfil S, de Jong D, Burger D, Arnó A, Balagué M, Clotet B. Ruiz L, et al. Among authors: clotet b. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):19-28. doi: 10.1097/00042560-199809010-00003. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732064 Clinical Trial.
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. García F, et al. Among authors: clotet b. J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35. doi: 10.1097/00042560-200009010-00004. J Acquir Immune Defic Syndr. 2000. PMID: 11064501 Clinical Trial.
1,153 results